PLoS ONE (Jan 2022)

Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer.

  • T Susanna Meijer,
  • Jan H N Dieters,
  • Eleonora M de Leede,
  • Lioe-Fee de Geus-Oei,
  • Jaap Vuijk,
  • Christian H Martini,
  • Arian R van Erkel,
  • Jacob Lutjeboer,
  • Rutger W van der Meer,
  • Fred G J Tijl,
  • Ellen Kapiteijn,
  • Alexander L Vahrmeijer,
  • Mark C Burgmans

DOI
https://doi.org/10.1371/journal.pone.0261939
Journal volume & issue
Vol. 17, no. 1
p. e0261939

Abstract

Read online

PurposePercutaneous hepatic perfusion with melphalan (M-PHP) is increasingly used in patients with liver metastases from various primary tumors, yet data on colorectal liver metastases (CRLM) are limited. The aim of this study was to prospectively evaluate the efficacy and safety of M-PHP in patients with CRLM.Materials and methodsProspective, single-center, single-arm phase II study of M-PHP with hemofiltration in patients with unresectable CRLM. Proven, extrahepatic metastatic disease was one of the exclusion criteria. Primary outcomes were overall response rate (ORR) and best overall response (BOR). Secondary outcomes were overall survival (OS), progression-free survival (PFS), hepatic PFS (hPFS), and safety.ResultsA total of 14 M-PHP procedures were performed in eight patients between March 2014 and December 2015. All patients (median age 56 years, ranging from 46 to 68) had received (extensive) systemic chemotherapy before entering the study. The ORR was 25.0%, with two out of eight patients showing partial response as BOR. Median OS was 17.3 months (ranging from 2.6 to 30.9) with a one-year OS of 50.0%. Median PFS and hPFS were 4.4 and 4.5 months, respectively. No serious adverse events occurred. Grade 3/4 hematologic adverse events were observed in the majority of patients, though all were transient and well-manageable.ConclusionM-PHP is a safe procedure with only limited efficacy in patients with unresectable CRLM who already showed progression of disease after receiving one or more systemic treatment regimens.